Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Vaccines, Blood & Biologics

September 18, 2001 Approval Letter - UltraQual HIV-1 RT-PCR Assay

Public Health Service
Food and Drug Administration
1401 Rockville Pike
Rockville, MD 20852-1448

September 18, 2001

Our STN Number: BL 103902

Andrew Conrad, Ph.D.
Chief Scientific Officer
National Genetics Institute
2440 S. Sepulveda Boulevard #130
Los Angeles, California 90064

Dear Dr. Conrad:

Your Biologics License Application (BLA) for the National Genetics Institute (NGI) UltraQualä Human Immunodeficiency Virus Type 1 Reverse Transcriptase Polymerase Chain Reaction (PCR) Assay (UltraQualä HIV-1 RT-PCR Assay) is approved effective this date. This assay, when used in combination with FDA approved pooling and resolution algorithms, is indicated for the qualitative detection of the human immunodeficiency virus type 1 (HIV-1) of ribonucleic acid (RNA) in pooled human Source Plasma comprised of equal aliquots of not more than --- individual plasma samples. This method may be used as an alternative to currently licensed HIV-1 p24 antigen tests for screening Source Plasma. National Genetics Institute is hereby authorized to introduce or deliver for introduction into interstate commerce the UltraQualä HIV-1 RT-PCR Assay performed at NGI's facilities under U.S. License No. 1582.

Under this authorization, you are approved to provide results of HIV-1 nucleic acid testing (NAT) of human Source Plasma pools at your Los Angeles facilities. Changes to the product, production processes, location of production processes, equipment, facilities, or responsible personnel are required to be reported to FDA as specified in Title 21 Code of Federal Regulations (CFR) Section 601.12.

All adverse reports should be submitted according to 21 CFR 600.80 to the Center for Biologics Evaluation and Research (CBER), HFM-210, Food and Drug Administration, 1401 Rockville Pike, Rockville, Maryland 20852-1448. In addition, safety related information obtained in the course of other relevant clinical studies should be reported in accordance with 21 CFR 312.32. It is also requested that distribution reports be submitted according to 21 CFR 600.81.

NGI may wish to submit any proposed introductory advertising and promotional campaign. If so, please submit three (3) copies of the proposed material in draft form with Part I of the FDA Form 2567/2253 to CBER, Advertising and Promotional Labeling Branch (APLB), HFM-602, 1401 Rockville Pike, Rockville, Maryland 20852-1448.

Promotional claims should be consistent with and not contrary to the approved labeling. No comparative claims or claims of superiority over other similar products should be made unless data to support such claims are submitted to and approved by the Center for Biologics Evaluation and Research. Final copies of advertising and promotional materials should be submitted at the time of use with Part II of FDA Form 2567/2253 to APLB. Please include copies of the approved labeling with your proposed or final copy of advertising and promotional materials submitted to CBER.

It is recommended that a copy of this letter be available for review at the time of FDA inspections.

Sincerely yours,


--- signature ---


Jay S. Epstein, M.D.
Office of Blood Research and Review
Center for Biologics Evaluation and Research


--- signature ---


Steven A. Masiello
Office of Compliance and Biologics Quality
Center for Biologics Evaluation and Research

Contact FDA

(800) 835-4709
(240) 402-8010
Consumer Affairs Branch (CBER)

Division of Communication and Consumer Affairs

Office of Communication, Outreach and Development

Food and Drug Administration

10903 New Hampshire Avenue

Building 71 Room 3103

Silver Spring, MD 20993-0002

Page Last Updated: 02/25/2010
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English